The study focuses on refractory metastatic prostate cancer, a form of prostate cancer that continues to grow and spread despite standard treatments. The investigational medication being examined is identified by the code name MK-5684, which is taken as a single oral tablet.

The purpose of the trial is to determine how a high-fat meal influences the pharmacokinetics of the drug—meaning how quickly and how much of the medication enters the bloodstream—and to observe any changes in steroid hormone levels such as testosterone over time. Healthy male volunteers receive the tablet twice: once after an overnight fast and once after eating a fatty meal, with a short break between the two dosing periods.

During each visit, blood samples are collected at several time points to measure the amount of drug and hormone levels in the plasma, the liquid part of blood. Participants are monitored for any side effects throughout the short study period, and all procedures are designed to be safe and well‑tolerated.